Join us for our upcoming free 60-minute webinar at 16:00 BST / 11:00 EDT / 17:00 CET on Wednesday 11th September 2024 to learn about our AAV development expertise and recent breakthroughs! Our speakers will delve into how the characterisation of the contents and surface of AAV capsids has helped identify factors influencing charge heterogeneity, and consequently, the potency of AAV products. To register for the webinar, please click here: https://lnkd.in/eykthwfW #AAV #Webinar #CDMO #ViralVectors #Bioprocessing
Oxford Biomedica
Pharmaceutical Manufacturing
Oxford, Oxfordshire 38,011 followers
A quality and innovation-led CDMO in cell and gene therapy
About us
Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com.
- Website
-
http://www.oxb.com
External link for Oxford Biomedica
- Industry
- Pharmaceutical Manufacturing
- Company size
- 501-1,000 employees
- Headquarters
- Oxford, Oxfordshire
- Type
- Public Company
- Founded
- 1995
- Specialties
- Gene therapy, Immunotherapy, Viral vector GMP manufacturing, and Cell and gene therapy
Locations
Employees at Oxford Biomedica
Updates
-
At OXB, we design optimal vectors to boost productivity and minimize the occurrence of partial capsids, resulting in a more cost-effective process and more powerful therapies. #AAV #ViralVectors #CellAndGeneTherapy #VectorEngineering
-
-
Next Thursday at 11am EDT, Dr. Serena Dollive, PhD, Senior Scientist II, will be presenting her group's work on characterizing AAV gene therapies using PacBio long-read sequencing at the 16th Annual Bioprocessing Summit in Boston. If you’d like to hear how we can quantitate residual impurities as well as vector subspecies all within one assay for deeper, more comprehensive understanding of vector batch content, be sure to listen to Serena’s talk! #Conference #Bioprocessing #CDMO #AAV #ViralVectors #CellAndGeneTherapy
-
-
As an innovation-led viral vector CDMO, we are constantly innovating to improve vector titre, quality, potency, safety and scalability, to speed up the time it takes our clients to move their programmes through clinical trials to GMP manufacturing. #CDMO #ViralVectors #Innovation #CellAndGeneTherapy #GMP
-
-
In this newly published, peer-reviewed paper, we demonstrate a 2-fold increase in AAV productivity through the use of a minimize helper plasmid containing deletions in the E2a and E4 adenovirus genes. The minimized helper plasmid generated reduced E4orf6 expression that was correlated with an increase in vector genome production. This finding highlights that native adenovirus gene expression utilized in most currently available helper plasmids does not provide the optimal conditions for AAV production and suggests that further fine-tuning helper gene expression could unlock additional titer increases. Read the paper here: https://lnkd.in/ehmZm2sQ #CDMO #ViralVectors #Innovation #CellAndGeneTherapy #AAV
-
-
This morning, we shared a trading update for the first half of 2024 showing the strong demand for CDMO services we are experiencing. We reiterate our medium-term financial guidance of a three-year revenue CAGR in excess of 35% for 2023-2026, to be profitable on an Operating EBITDA level in 2025, with Operating EBITDA margins in excess of 20% by the end of 2026. Read the press release here: https://lnkd.in/eSHRXWgZ #CDMO #ViralVectors #CellAndGeneTherapy
-
At OXB, we know the challenges and we're ready to help. We push the boundaries of innovation developing technical solutions to help overcome industry challenges. Learn more about our solutions at OXB.com. #CDMO #ViralVectors #CellAndGeneTherapy
-
-
Just as athletes from around the world come together to compete in the spirit of unity in Paris, we operate as #OneOXB, collaborating across our global network of sites to accelerate access to life-changing therapies. At OXB we celebrate our own wins and our team’s dedication, determination, and innovation. Collaboration and team spirit are embedded into everything we do, and together, we are not just a network of sites, but one cohesive force, working hard to transform lives through cell and gene therapy. #Global #CDMO #ViralVectors #CellAndGeneTherapy #Collaboration
-
Today, we are pleased to announce that Laurence Espinasse, General Counsel at Institut Mérieux joined our Board as a Non-Executive Director on 24th July. Laurence has significant expertise across the legal and healthcare sectors and an impressive track record with more than 20 years of experience working in corporate law, contract law and compliance/risks. Welcome to OXB, Laurence! Read the press release here: https://lnkd.in/dQurEkcX #BoardOfDirectors #CorporateGovernance #CDMO #ViralVectors #CellAndGeneTherapy
-
-
Opened in 2021, Oxbox is our largest UK manufacturing facility spanning 84,000 sq. ft. This impressive facility is located on the outskirts of Oxford and contains 45,000 sq. ft. of MHRA approved commercial manufacturing space with 4 GMP vector production suites and 2 fill finish suites. Oxbox also houses supporting areas such as warehousing, cold chain facilities, QC laboratories and fallow area to support future expansion plans. If you’re looking for a CDMO to support you with your viral vector development needs, why not come and visit us? Email [email protected] to schedule a tour. #CDMO #ViralVectors #GMP #Manufacturing #CellAndGeneTherapies #AdvancedTherapies #Lenti #AAV #Adeno